Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effect of Oxybutynin on Opioid Use After Urologic Surgery in Children

14 novembre 2026 mis à jour par: Bryce Weber, University of Calgary

A Randomized Double-Blind Placebo-Controlled Trial Evaluating the Opioid-Sparing Effect of Preoperative Oxybutynin in Children Undergoing Urologic Reconstruction

The goal of this clinical trial is to determine whether giving oxybutynin before urologic reconstruction surgery reduces the amount of opioid pain medication needed in children. Oxybutynin is a medication that helps reduce bladder spasms, which can cause pain and discomfort after surgery.

The main question this study aims to answer is:

Does giving oxybutynin before surgery reduce the amount of opioid pain medication children need during the first 6 hours after surgery?

Researchers will compare oxybutynin with a placebo (a tablet containing no active medication) to see whether oxybutynin reduces opioid use after surgery.

Aperçu de l'étude

Statut

Pas encore de recrutement

Description détaillée

Background

Children undergoing pediatric urologic reconstruction, such as pyeloplasty and hypospadias repair, frequently require urinary drainage via ureteral stent and/or urethral catheter. These tools cause the bladder to contract involuntarily, mediated by muscarinic receptors (i.e., bladder spasms). This leads to increased catheter-related bladder discomfort (CRBD), bladder spasm-associated pain and postoperative opioid use.

Oxybutynin, an antimuscarinic agent, reduces the occurrence of bladder spasms and thus the number and severity of CRBD events and bladder spasm-related pain. This reduction in discomfort/pain may contribute to decreased postoperative opioid use, as suggested by retrospective pediatric data.

Postoperative management of urologic reconstruction surgeries includes PRN administration of opioids and oxybutynin to treat bladder spasm-related discomfort/pain according to institutional practice and prior pediatric urology literature. Oxybutynin takes 1 hour to reach its maximal plasma concentration, during which time significant bladder spasm-related symptoms may already be present when the child is awake. However, opioids such as morphine achieve their maximal effects within 10 minutes. Because opioids are much faster-acting than oxybutynin, this may increase the likelihood of concomitant administration when the child is awake with discomfort/pain. We are therefore considering using oxybutynin preoperatively, rather than just postoperatively PRN, since its plasma concentration will already be maximal or near-maximal upon waking, which may lead to less CRBD, bladder spasm-related pain, and postoperative opioid use.

This study aims to reduce the use of opioids to treat pediatric patients undergoing urologic reconstruction. Opioids carry significant side effects that include nausea, vomiting, respiratory depression, addiction, urinary retention, tolerance, and constipation. Combined with the ongoing opioid epidemic, there is an increased effort among caregivers, including nurses and physicians, to find other means to reduce pain in pediatric patients.

Opioid therapy has also been shown not to be effective in treating bladder spasm-related symptoms (e.g., CRBD, bladder spasm-related pain). As opposed to opioids, oxybutynin directly targets bladder spasm-associated symptoms, and may reduce the severity of side effects. Side effects of oxybutynin include dry mouth, constipation, dizziness, urinary retention, and blurry vision.

Emerging pediatric urology data suggest that a single preoperative dose may reduce early postoperative opioid requirements. However, current evidence is retrospective and non-randomized. There is no high-quality randomized pediatric study evaluating the opioid sparing effects of preoperative oxybutynin administration in pediatric patients undergoing urologic reconstruction.

Study Need, Importance, and Hypothesis

Urologic reconstruction surgeries requiring a stent and/or catheter can be associated with significant CRBD, bladder-spasm associated pain and morbidity. With the growing recognition of the need to decrease opioid medication, our primary objective is to assess whether the administration of preoperative oxybutynin reduces opioid use. We hypothesize that preoperative oxybutynin reduces early postoperative opioid use in children undergoing pyeloplasty or hypospadias repair.

Type d'étude

Interventionnel

Inscription (Estimé)

200

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Alberta
      • Calgary, Alberta, Canada, T2B6A8
        • Alberta Children's Hospital
        • Chercheur principal:
          • Bryce Weber
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

Pas plus vieux que 17 ans (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • All children aged 0 to 17 years old admitted for pyeloplasty or hypospadias repair. There is no minimum weight for inclusion

Exclusion Criteria:

  • Contraindications to anticholinergic medications
  • Urinary retention disorders
  • Gastrointestinal obstruction/ileus
  • Contraindications to anesthetic protocol, including 1) allergy to any anesthetic medication in protocol, 2) refusal of regional technique, 3) contraindications to ketorolac (i.e., recent GI bleed, recent intracranial bleed, renal dysfunction, acute kidney injury)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Preoperative Oxybutynin

Participants will receive oxybutynin 0.2 mg/kg (to a maximum dose of 5 mg), orally administered by the day surgery nurse in the day surgery holding area prior to surgery.

Participants will receive oxybutynin 0.2 mg/kg (to a maximum dose of 5 mg), orally administered by the day surgery nurse in the day surgery holding area prior to surgery.

Comparateur placebo: Preoperative Placebo

Participants will receive a matching placebo tablet, orally administered by the day surgery nurse in the day surgery holding area prior to surgery.

Participants will receive a matching placebo tablet, orally administered by the day surgery nurse in the day surgery holding area prior to surgery.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Total Cumulative Postoperative Opioid Consumption (MME/kg)
Délai: From the end of surgery through 6 hours postoperatively

Total cumulative morphine milligram equivalents per kilogram (MME/kg) administered within 6 hours after surgery

From the end of surgery through 6 hours postoperatively

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Proportion of Participants Receiving Postoperative Opioids
Délai: From the end of surgery through 6 hours postoperatively

Whether any opioid medication was administered within 6 hours after surgery (yes/no)

From the end of surgery through 6 hours postoperatively
Postoperative Pain Scores (NRS/FLACC)
Délai: At 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 6 hours following postoperative removal of the laryngeal mask airway or endotracheal tube

Pain assessed using age-appropriate validated scales: the Numeric Rating Scale (NRS; 0-10) or the Face, Legs, Activity, Cry, Consolability (FLACC; 0-10) scale. Higher scores indicate greater pain.

At 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 6 hours following postoperative removal of the laryngeal mask airway or endotracheal tube
Proportion of Participants Receiving Postoperative Rescue Oxybutynin
Délai: From the end of surgery through 6 hours postoperatively

Whether oxybutynin was administered as needed (PRN) within 6 hours after surgery (yes/no).

From the end of surgery through 6 hours postoperatively
Total Cumulative Postoperative Oxybutynin Consumption (mg/kg)
Délai: From the end of surgery through 6 hours postoperatively

Total cumulative dose of oxybutynin administered per kilogram of body weight during the first 6 hours after surgery.

From the end of surgery through 6 hours postoperatively
Incidence of Adverse Events
Délai: From preoperative study medication administration through postoperative discharge

Occurrence of adverse events, including dry mouth, flushing, tachycardia, agitation, sedation, and urinary retention.

From preoperative study medication administration through postoperative discharge

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 novembre 2028

Achèvement de l'étude (Estimé)

1 novembre 2028

Dates d'inscription aux études

Première soumission

23 octobre 2026

Première soumission répondant aux critères de contrôle qualité

29 octobre 2026

Première publication (Réel)

2 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

14 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner